Christian Jackisch1, Daniil Stroyakovskiy2, Xavier Pivot3, Jin Seok Ahn4, Bohuslav Melichar5, Shin-Cheh Chen6, Christoph Meyenberg7, Nedal Al-Sakaff8, Dominik Heinzmann8, Roberto Hegg9. 1. Department of Obstetrics and Gynecology, Sana Klinikum Offenbach GmbH, Offenbach, Germany. 2. Chemotherapeutic Department, City Clinical Oncology Hospital 62, Moscow, Russian Federation. 3. Centre de Lutte contre le Cancer Paul Strauss de Strasbourg, Strasbourg, France. 4. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 5. Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic. 6. Department of Surgery, Chang Gung Memorial Hospital, Taoyuan City, Taiwan. 7. Biostatistics, Product Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland. 8. Product Development-Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland. 9. Department of Gynecology and Obstetrics, Hospital Pérola Byington, São Paulo, Brazil.
Abstract
IMPORTANCE: Confirmation of long-term comparability between subcutaneous and intravenous trastuzumab is essential. OBJECTIVE: To evaluate efficacy and safety of subcutaneous trastuzumab compared with that of intravenous trastuzumab for patients with ERBB2 (HER2)-positive early breast cancer after 6 years' follow-up in the HannaH (Enhanced Treatment With Neoadjuvant Herceptin) trial. DESIGN, SETTING, AND PARTICIPANTS: Open-label, prospective, multicenter, international, neoadjuvant-adjuvant, randomized, phase 3 noninferiority clinical trial (primary end points: pathologic complete response and serum trough concentration predose cycle 8) conducted for 596 patients with ERBB2-positive early breast cancer enrolled from October 19, 2009, to December 1, 2010. INTERVENTIONS: Eligible patients received 8 cycles of chemotherapy (4 cycles of docetaxel, 75 mg/m2, followed by 4 cycles of fluorouracil, 500 mg/m2, epirubicin, 75 mg/m2, and cyclophosphamide, 500 mg/m2) with either fixed-dose subcutaneous trastuzumab, 600 mg, or intravenous trastuzumab (loading dose, 8 mg/kg; maintenance dose, 6 mg/kg) every 3 weeks in the neoadjuvant setting. Patients received an additional 10 cycles of subcutaneous trastuzumab or intravenous trastuzumab (according to their initial randomization) after surgery in the adjuvant setting to complete 1 year of anti-ERBB2 therapy. MAIN OUTCOMES AND MEASURES: Event-free and overall survival rates were calculated using the Kaplan-Meier method. Hazard ratios were estimated by Cox proportional hazards regression. Adverse events and serious adverse events were graded per standard criteria. RESULTS: In total, 294 women (mean [SD] age, 50.3 [11.1] years) treated with subcutaneous trastuzumab and 297 women (mean [SD] age, 49.5 [10.8] years) treated with intravenous trastuzumab were included in respective intention-to-treat populations. Six-year event-free survival rates (65% in both study groups; hazard ratio, 0.98; 95% CI, 0.74-1.29) and overall survival rates (84% in both study groups; hazard ratio, 0.94; 95% CI, 0.61-1.45) were similar between the subcutaneous and intravenous trastuzumab groups. Patients achieving a total pathologic complete response had longer event-free survival and higher 6-year overall survival rates than those with residual disease. Incidence of adverse events (290 of 297 [97.6%] vs 282 of 298 [94.6%]), grade 3 or higher adverse events (158 of 297 [53.2%] vs 160 of 298 [53.7%]), cardiac events (44 of 297 [14.8%] vs 42 of 298 [14.1%]), and serious adverse events (65 of 297 [21.9%] vs 45 of 298 [15.1%]) was comparable between the subcutaneous and intravenous trastuzumab treatment groups. CONCLUSIONS AND RELEVANCE: This final analysis of the HannaH trial further confirms the comparable efficacy and safety of subcutaneous and intravenous trastuzumab and highlights the suitability of subcutaneous trastuzumab as an alternative route of administration for patients with ERBB2-positive early breast cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00950300.
IMPORTANCE: Confirmation of long-term comparability between subcutaneous and intravenous trastuzumab is essential. OBJECTIVE: To evaluate efficacy and safety of subcutaneous trastuzumab compared with that of intravenous trastuzumab for patients with ERBB2 (HER2)-positive early breast cancer after 6 years' follow-up in the HannaH (Enhanced Treatment With Neoadjuvant Herceptin) trial. DESIGN, SETTING, AND PARTICIPANTS: Open-label, prospective, multicenter, international, neoadjuvant-adjuvant, randomized, phase 3 noninferiority clinical trial (primary end points: pathologic complete response and serum trough concentration predose cycle 8) conducted for 596 patients with ERBB2-positive early breast cancer enrolled from October 19, 2009, to December 1, 2010. INTERVENTIONS: Eligible patients received 8 cycles of chemotherapy (4 cycles of docetaxel, 75 mg/m2, followed by 4 cycles of fluorouracil, 500 mg/m2, epirubicin, 75 mg/m2, and cyclophosphamide, 500 mg/m2) with either fixed-dose subcutaneous trastuzumab, 600 mg, or intravenous trastuzumab (loading dose, 8 mg/kg; maintenance dose, 6 mg/kg) every 3 weeks in the neoadjuvant setting. Patients received an additional 10 cycles of subcutaneous trastuzumab or intravenous trastuzumab (according to their initial randomization) after surgery in the adjuvant setting to complete 1 year of anti-ERBB2 therapy. MAIN OUTCOMES AND MEASURES: Event-free and overall survival rates were calculated using the Kaplan-Meier method. Hazard ratios were estimated by Cox proportional hazards regression. Adverse events and serious adverse events were graded per standard criteria. RESULTS: In total, 294 women (mean [SD] age, 50.3 [11.1] years) treated with subcutaneous trastuzumab and 297 women (mean [SD] age, 49.5 [10.8] years) treated with intravenous trastuzumab were included in respective intention-to-treat populations. Six-year event-free survival rates (65% in both study groups; hazard ratio, 0.98; 95% CI, 0.74-1.29) and overall survival rates (84% in both study groups; hazard ratio, 0.94; 95% CI, 0.61-1.45) were similar between the subcutaneous and intravenous trastuzumab groups. Patients achieving a total pathologic complete response had longer event-free survival and higher 6-year overall survival rates than those with residual disease. Incidence of adverse events (290 of 297 [97.6%] vs 282 of 298 [94.6%]), grade 3 or higher adverse events (158 of 297 [53.2%] vs 160 of 298 [53.7%]), cardiac events (44 of 297 [14.8%] vs 42 of 298 [14.1%]), and serious adverse events (65 of 297 [21.9%] vs 45 of 298 [15.1%]) was comparable between the subcutaneous and intravenous trastuzumab treatment groups. CONCLUSIONS AND RELEVANCE: This final analysis of the HannaH trial further confirms the comparable efficacy and safety of subcutaneous and intravenous trastuzumab and highlights the suitability of subcutaneous trastuzumab as an alternative route of administration for patients with ERBB2-positive early breast cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00950300.
Authors: Miguel Martin; Frankie A Holmes; Bent Ejlertsen; Suzette Delaloge; Beverly Moy; Hiroji Iwata; Gunter von Minckwitz; Stephen K L Chia; Janine Mansi; Carlos H Barrios; Michael Gnant; Zorica Tomašević; Neelima Denduluri; Robert Šeparović; Erhan Gokmen; Anna Bashford; Manuel Ruiz Borrego; Sung-Bae Kim; Erik Hugger Jakobsen; Audrone Ciceniene; Kenichi Inoue; Friedrich Overkamp; Joan B Heijns; Anne C Armstrong; John S Link; Anil Abraham Joy; Richard Bryce; Alvin Wong; Susan Moran; Bin Yao; Feng Xu; Alan Auerbach; Marc Buyse; Arlene Chan Journal: Lancet Oncol Date: 2017-11-13 Impact factor: 41.316
Authors: C Jackisch; S-B Kim; V Semiglazov; B Melichar; X Pivot; C Hillenbach; D Stroyakovskiy; B L Lum; R Elliott; H A Weber; G Ismael Journal: Ann Oncol Date: 2014-11-17 Impact factor: 32.976
Authors: Gunter von Minckwitz; Marion Procter; Evandro de Azambuja; Dimitrios Zardavas; Mark Benyunes; Giuseppe Viale; Thomas Suter; Amal Arahmani; Nathalie Rouchet; Emma Clark; Adam Knott; Istvan Lang; Christelle Levy; Denise A Yardley; Jose Bines; Richard D Gelber; Martine Piccart; Jose Baselga Journal: N Engl J Med Date: 2017-06-05 Impact factor: 91.245
Authors: X Pivot; J Gligorov; V Müller; G Curigliano; A Knoop; S Verma; V Jenkins; N Scotto; S Osborne; L Fallowfield Journal: Ann Oncol Date: 2014-07-28 Impact factor: 32.976
Authors: Erwin De Cock; Xavier Pivot; Nik Hauser; Sunil Verma; Persefoni Kritikou; Douglas Millar; Ann Knoop Journal: Cancer Med Date: 2016-01-25 Impact factor: 4.452
Authors: Ross Mudgway; Carlos Chavez de Paz Villanueva; Ann C Lin; Maheswari Senthil; Carlos A Garberoglio; Sharon S Lum Journal: Ann Surg Oncol Date: 2020-03-10 Impact factor: 5.344
Authors: Sherko Kuemmel; Carlo A Tondini; Jacinta Abraham; Zbigniew Nowecki; Bartosz Itrych; Erika Hitre; Bogusława Karaszewska; Alejandro Juárez-Ramiro; Flavia Morales-Vásquez; Jose Manuel Pérez-García; Servando Cardona-Huerta; Estefania Monturus; Marco Sequi; Eleonora Restuccia; Mark Benyunes; Miguel Martín Journal: Breast Cancer Res Treat Date: 2021-03-21 Impact factor: 4.872
Authors: Yohei Ozawa; Kristin C Hicks; Christine M Minnar; Karin M Knudson; Jeffrey Schlom; Sofia R Gameiro Journal: Oncoimmunology Date: 2021-05-03 Impact factor: 8.110